An International Journal of Otorhinolaryngology Clinics

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 2 , ISSUE 3 ( September-December, 2010 ) > List of Articles

REVIEW ARTICLE

Chemoradiation for Laryngeal Cancer: Present Scenario

Adwaita Gore, Pushkal Dwiwedi, Boman Dhabhar, Tapan K Saikia

Keywords : Cetuximab,Chemoradiation,EGFR,Head and neck cancer,Laryngeal cancer,Radiotherapy

Citation Information : Gore A, Dwiwedi P, Dhabhar B, Saikia TK. Chemoradiation for Laryngeal Cancer: Present Scenario. Int J Otorhinolaryngol Clin 2010; 2 (3):215-221.

DOI: 10.5005/jp-journals-10003-1039

Published Online: 00-12-2010

Copyright Statement:  Copyright © 2010; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

The management of locally advanced squamous cell carcinoma of the larynx is complex. Data from recent clinical trials have refined the use of existing therapies, such as radiation therapy and chemotherapy, and providing new treatment options, such as cetuximab. Selecting the most appropriate treatment for an individual patient requires a multidisciplinary approach and careful assessment of the relative advantages and disadvantages of each treatment approach. Chemoradiation is more effective than conventional radiation therapy, but also more toxic. Cetuximab plus radiation therapy is more effective than radiation alone and does not substantially increase radiation-related toxicity. Multimodality approach for laryngeal cancer has shown better organ preservation rates and survival. Ideally, multidisciplinary teams should weigh all these factors when making individual treatment decisions. Data from current trials will help further optimize multimodality treatment for Laryngeal Cancer.

PDF Share
  1. Recent Advances in Combined Modality Therapy. The Oncologist 2010;15:372–81.
  2. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-Analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949–55.
  3. Radiother Oncol 2009;92:4–14.
  4. N Engl J Med 2003;349:2091–98.
  5. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002;13:995–1006.
  6. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685–90.
  7. N Engl J Med 2007;357:1695–1704.
  8. N Engl J Med 2007;357:1705–15.
  9. Int J Radiat Oncol Biol Phys 2004;58:966–71.
  10. N Engl J Med 2006;354:567–78.
  11. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21–28.
  12. ASCO 2009. Abstract 6010.
  13. N Engl J Med 2004;350:1937–44.
  14. N Engl J Med 2004;350:1945–52.
  15. Int J Radiat Oncol Biol Phys 1991;20: 243–46.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.